Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12624000889550p
Ethics application status
Submitted, not yet approved
Date submitted
3/07/2024
Date registered
22/07/2024
Date last updated
22/07/2024
Date data sharing statement initially provided
22/07/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Personalised transcranial alternating current stimulation as a novel therapeutic treatment for post-traumatic stress disorder
Query!
Scientific title
Evaluating the effects of personalised alpha-tACS on alpha power in participants with post-traumatic stress disorder (PTSD)
Query!
Secondary ID [1]
312444
0
None
Query!
Universal Trial Number (UTN)
NA
Query!
Trial acronym
tACS for PTSD
Query!
Linked study record
NA
Query!
Health condition
Health condition(s) or problem(s) studied:
PTSD
334271
0
Query!
Condition category
Condition code
Mental Health
330934
330934
0
0
Query!
Other mental health disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Transcranial alternating current stimulation (tACS) is a form of non-invasive brain stimulation that externally applies weak oscillatory electrical currents (typically 1-2mA) at a specified frequency to the brain. tACS can modulate cortical excitability through entrainment and spike-timing dependent plasticity. Entrainment is a primary mechanism proposed to drive the modulatory effects of tACS on cortical excitability and refers to the synchronisation of endogenous brain oscillations to another (external) driving frequency. Entrainment effects can be optimised by matching the tACS frequency to the individual’s dominant endogenous frequency for a particular band of oscillation, in this instance the individual’s endogenous alpha frequency. Electroencephalography (EEG) recordings will be used to determine a subject’s dominant endogenous oscillatory frequency within the alpha band, which will then be used to personalise stimulation frequency for tACS therapy.
Administration of tACS will be provided using the Rio transceiver device (eemagine Medical Imaging Solutions GmbH), a mobile device for recording EEG signals combined with transcranial alternating current stimulation (tACS). Controlled electrical current stimulation can be triggered from a software application, via external triggers, or via an internal feature extraction pipeline with minimum latency and jitter. The device has been produced and appropriately tested in the ISO accredited facilities ANT Neuro in Germany. The device delivers a voltage controlled current across stimulation electrodes made of conductive rubber encased in commercially supplied saline soaked sponges and are held in place with a fitted cap.
The study will use a cross-over, double blind design. Potential participants will complete an initial pre-screen phone call with a research team member. If deemed eligible, participants will complete a consent and baseline session. Participants will provide demographic information, medical history and complete clinician rated assessments and self-report assessments throughout the study period; including MINI-DSM5, CAPS-5, MINI, PCL-5, AQoL and PHQ.
Resting-state electroencephalography (EEG; 64-channels) will be completed prior to the start of each treatment block and at the end of each treatment block (conducted at the ANU). Participants will complete two treatment blocks where they will receive 15 sessions, daily (Monday - Friday) for 3 weeks of personalised alpha-tACS and 15 sessions, daily (Monday - Friday) for 3 weeks of sham-tACS. The EEG data recorded will be used to determine participant's individual alpha frequency (IAF), during active treatment block (alpha-tACS condition) the stimulation frequency will be uploaded onto the device.
There will be a 4-week break (minimum 4, maximum 8) between blocks and the order of completion counterbalanced across the participant pool. Resting-state EEG (10 channels) will be recorded for 3 minutes prior to, and following, each treatment session (i.e., daily) to track changes in alpha power and posterior-frontal connectivity across treatment periods.
On site: Treatment will be administered by a study researcher. The study researcher will provide clear instructions on where the participant is to be seated and demonstrate how to prepare the tACS-EEG cap and fit it to the participant's head. Administration of tACS and recording with EEG will be automatically triggered while participants complete a series of working memory tasks. Following the completion of the working memory tasks, the study researcher will remove the cap and demonstrate how to clean and care for the equipment, Sessions on site are not limited, participants will be able to attend all sessions on site until competency to carry out at home session is clearly demonstrated.
At home: All procedures outlined above will be presented to participants in a way that will teach them how to self-administer treatment at home. The treatment itself is pre-programmed into the device and triggered by participants as they complete a highly guided series of working memory tasks. We will use a checklist to assess competency before participants start treatment at home. The checklist requires researchers to assess and sign off on participants' use of the device on several items pertaining to head and cap preparation, machine preparation and stimulation, steps involved during and post stimulation. The participants will only take home the device for self-administration when they have passed this assessment and feel confident with using the device. When participants are competent and feel comfortable to conduct treatments at home, we can monitor use for several sessions over zoom and be available for troubleshooting, if required.
For all active tACS treatment session, a peak-to-peak intensity of 2 mA will be administered for 20 minutes, with a 10 s ramp-up and a 10 s ramp-down every time the stimulation starts and stops. The frequency of the tACS will be matched to the participants dominant alpha frequency measured with EEG at baseline and end of the break period.
Query!
Intervention code [1]
328950
0
Treatment: Devices
Query!
Comparator / control treatment
Sham-tACS
In the sham condition, the current will be delivered at an intensity of 2 mA in the first and last 30 seconds (including a 10 s ramp-up/down) at the IAF, to emulate sensations associated with tACS administration without producing any enduring physiological effects.
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
338696
0
Changes in Alpha power between active treatment and sham
Query!
Assessment method [1]
338696
0
Measured using EEG
Query!
Timepoint [1]
338696
0
Pre-treatment block and post-treatment block for personalised alpha-tACS and sham-tACS
Query!
Secondary outcome [1]
437061
0
Changes in post-traumatic stress disorder (PTSD) severity
Query!
Assessment method [1]
437061
0
Measured using clinician administered PTSD Scale (CAPS-5)
Query!
Timepoint [1]
437061
0
Baseline, post-treatment block 1, pre- and post-treatment block 2 and at 4-week follow-up
Query!
Secondary outcome [2]
437062
0
Changes in PTSD severity
Query!
Assessment method [2]
437062
0
Measured using self-reported PTSD Checklist (PCL-5)
Query!
Timepoint [2]
437062
0
Baseline, post-treatment block 1, pre- and post-treatment block 2 and at 4-week follow-up
Query!
Secondary outcome [3]
437063
0
Changes in clinical severity of depression
Query!
Assessment method [3]
437063
0
Clinician rated Montgomery-Asberg Depression Rating Scale (MADRS)
Query!
Timepoint [3]
437063
0
Baseline, post-treatment block 1, pre- and post-treatment bloc 2 and at 4-week follow-up
Query!
Secondary outcome [4]
437064
0
Changes in participants' quality of life
Query!
Assessment method [4]
437064
0
Assessed using self-report questionnaire Assessment of Quality-of-Life Scale
Query!
Timepoint [4]
437064
0
Baseline, post-treatment block 1, pre- and post-treatment bloc 2 and at 4-week follow-up
Query!
Eligibility
Key inclusion criteria
Aged between 18-80 years of age
Clinician-Administered PTSD Scale (CAPS-5) total score of moderate-severe (greater than or equal to 20)
No change or initiation of new medication (antidepressant or other psychoactive) in the four weeks prior to screening
Demonstrated capacity to give informed consent
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Inability to provide informed consent
Medically unstable
Concomitant active neurological disorder
Individuals who are pregnant or breastfeeding
Active suicidal intent
Any psychotic disorder or current active psychotic symptoms
Meets criteria for current DSM 5 alcohol or substance dependence
Borderline personality disorder judged by an investigator to prevent appropriate engagement in the study
Individuals who have intracranial implants
Another AXIS I or II disorder judged to impact on the likelihood of response to treatment
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation to treatment group is concealed; by the research staff contacting the study investigators, after the participant is deemed eligible and has consented for the study.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Participants will be randomly allocated to study group using simple randomisation techniques i.e. using a computerised sequence generation
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Not Applicable
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Sample Size
A within-subjects repeated measures ANOVA with 80% power and a medium effect size (f = .25) will require a minimum of 24 subjects to detect a difference in EEG outcomes (4 measurements with 64 channels), 21 subjects for clinical CAPS-5 outcomes (5 measurements), and 15 subjects for clinical PCL-5 outcomes (9 measurements). Therefore, we will include 26 subjects in this study.
EEG Variables
Following processing of the EEG data, the Randomised Graphical User Interface (RAGU) will be used to determine if differences between groups in overall alpha power or the distribution of alpha activity are present at occipitoparietal and frontal regions. RAGU uses powerful randomization statistics to make comparisons between groups including activity from all electrodes and time points simultaneously, while still using robust multiple comparison controls. Differences detected at the scalp level using this approach indicate differences in the underlying sources generating the neural activity.
Behavioural Variables
We will use mixed model analyses to study the change in PTSD severity across time. The repeated measurements of outcome variables (e.g., CAPS-5 and PCL-5) will be analysed by fitting linear mixed models using restricted maximum likelihood (REML) – this will allow all available data to be used without the need for imputation of missing values, the selection of the most suitable variance-covariance model for the repeated measures, using Akaike’s Information Criterion, and the investigation of commonality of any nonlinear trends over time via smoothing splines. The F-test will be used to test for a treatment by time interaction and comparisons between treatment conditions at each time point will be based on t-tests that utilize the predicted means and standard errors of difference that are recovered from the fitted mixed model. Diagnostic plots of residuals will be assessed and if deemed necessary, variance-stabilizing transformations will be applied to the outcome variables and inferences will be based on the analyses conducted on the transformed scale. In a series of exploratory analyses, mixed models with covariates for gender, age and time since diagnosis, order of treatment (sham v active), and their interactions with treatment condition and time, will be fitted to identify possible moderating effects. ¬
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
2/09/2024
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
26/06/2026
Query!
Actual
Query!
Date of last data collection
Anticipated
23/10/2026
Query!
Actual
Query!
Sample size
Target
26
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
ACT
Query!
Funding & Sponsors
Funding source category [1]
316861
0
University
Query!
Name [1]
316861
0
Australian National University SMP Fast Grants Seed Funding Scheme 2024
Query!
Address [1]
316861
0
Query!
Country [1]
316861
0
Australia
Query!
Primary sponsor type
University
Query!
Name
Australian National University
Query!
Address
Query!
Country
Australia
Query!
Secondary sponsor category [1]
319100
0
None
Query!
Name [1]
319100
0
Query!
Address [1]
319100
0
Query!
Country [1]
319100
0
Query!
Ethics approval
Ethics application status
Submitted, not yet approved
Query!
Ethics committee name [1]
315620
0
ACT Health Human Research Ethics Committee
Query!
Ethics committee address [1]
315620
0
https://health.act.gov.au/act-health-system/research-data-and-publications/research/research-ethics-and-governance
Query!
Ethics committee country [1]
315620
0
Australia
Query!
Date submitted for ethics approval [1]
315620
0
03/07/2024
Query!
Approval date [1]
315620
0
Query!
Ethics approval number [1]
315620
0
Query!
Summary
Brief summary
Brain waves (also known as neural oscillations) in the brain’s default mode network (DMN) and visual cortex (VC) appear to be functionally and clinically relevant targets for the treatment of post-traumatic stress disorder (PTSD). Novel non-invasive brain stimulation techniques can directly target neural oscillations, potentially providing a safe and effective means to treat this complex disorder. Using transcranial alternating current stimulation (tACS), this research project will directly investigate for the first time whether stimulating alpha oscillations (8-12 Hz) to treat pathophysiological DMN activity results in improved clinical outcomes in patients with PTSD. This essential research is a crucial first step in demonstrating the potential of tACS as a novel therapeutic treatment option for those with PTSD. The aim of the proposed research is to conduct an exploratory study demonstrating the behavioural and electrophysiological impact of personalised tACS in participants with PTSD. Specifically, we will aim to confirm whether we can successfully use personalised tACS to enhance alpha oscillations in the prefrontal cortex and visual cortex to reduce clinical symptoms in participants with PTSD.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
135282
0
Dr Stephanie Gotsis
Query!
Address
135282
0
Rm 1.46, Florey Building, 54 Mills Road, Australian National University ACT 2601
Query!
Country
135282
0
Australia
Query!
Phone
135282
0
+61 2 6125 4153
Query!
Fax
135282
0
Query!
Email
135282
0
[email protected]
Query!
Contact person for public queries
Name
135283
0
Jeydhurga Raveendran
Query!
Address
135283
0
Rm 1.46, Florey Building, 54 Mills Road, The Australian National University, Canberra ACT, 2601
Query!
Country
135283
0
Australia
Query!
Phone
135283
0
+61 2 6125 4153
Query!
Fax
135283
0
Query!
Email
135283
0
[email protected]
Query!
Contact person for scientific queries
Name
135284
0
Stephanie Gotsis
Query!
Address
135284
0
Rm 1.46, Florey Building, 54 Mills Road, Australian National University ACT 2601
Query!
Country
135284
0
Australia
Query!
Phone
135284
0
+61 2 6125 4153
Query!
Fax
135284
0
Query!
Email
135284
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF